Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

On Thursday, Gilead Sciences Inc GILD announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).

The TROPiCS-04 study evaluated Trodelvy (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.

Also Read: Gilead’s Aggressive Push Beyond HIV Treatments – Plans To Increase Cancer-Focused CAR-T Treatment Production.

The study did not meet the primary endpoint of overall survival (OS) in the intention-to-treat (ITT) population.

A numerical improvement in OS favoring Trodelvy was observed, and trends in improvement for select pre-specified subgroups and secondary endpoints of progression-free survival and overall response rate were also shown.

In the overall study population, there was a higher number of deaths due to adverse events with Trodelvy compared to TPC, which were primarily observed early in treatment and related to neutropenic complications, including infection.

Gilead will further investigate these data and is working to reiterate to treating physicians the importance of granulocyte-colony stimulating factor (G-CSF) use to prevent neutropenic complications.

Trodelvy has a Boxed Warning for severe or life-threatening neutropenia.

“There are no changes to the known safety profile of Trodelvy for the approved breast cancer indications or other investigational uses,” the company said.

Gilead continues to analyze the data and will discuss the results and next steps with the FDA.

In the U.S., Trodelvy has an accelerated approval indication for patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials, including the TROPiCS-04 study.

Price Action: GILD shares were trading lower by 2.23% at $62.65 premarket at the last check on Friday.

Photo via Wikimedia Commons